Date: 2014-10-20
Type of information: Presentation of results at a congress
phase:
Announcement: presentation of results at Vaccines 2014, taking place in London from 20-22 October
Company: Mucosis (The Netherlands)
Product: SynGEM®
Action
mechanism: SynGEM® is a stabilized recombinant vaccine delivered intranasally to prevent respiratory syncytial virus (RSV) infection.
Disease: respiratory syncytial virus (RSV)
Therapeutic area: Infectious diseases
Country:
Trial details:
Latest
news: * On October 20, 2014, Mucosis, a clinical stage biotechnology company using a proprietary technology platform to develop next-generation needle-free human vaccines for infectious diseases, announced that the company will present research on its lead intranasal vaccine candidate SynGEM®, a vaccine candidate being researched to prevent infection with respiratory syncytial virus (RSV), at Vaccines 2014, taking place in London from 20-22 October. SynGEM® uses Mucosis’s proprietary Mimopath® platform to activate mucosal defenses, allowing more effective protection against infectious diseases. The data presented will include updates on the development of Mucosis’s unique stable prefusion form of the F vaccine antigen, effective against RSV particularly due to the powerful virus neutralizing antibodies it elicits. Results from preclinical studies of SynGEM® in animal models will also be included. “SynGEM®: An intranasal prefusion-like RSV F subunit vaccine,” authored by Bert Jan Haijema, Maarten van Roosmalen, Ivy Widjaja, Alan Rigter of Mucosis, Xander de Haan, Peter Rottier of Utrecht University and Kees Leenhouts, has been presented by Dr. Leenhouts, at Vaccines 2014.
